TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19565411

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for GPs
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (no MI training)
Number of subjects: 265
Study: 16957432

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1% in combination with benzoyl peroxide/clindamycin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tretinoin microsphere 0.04% in combination with benzoyl peroxide/clindamycin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tazarotene cream 0.05% in combination with benzoyl peroxide/clindamycin
Number of subjects: 35
Study: 15532202

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg, administered 1 hour before sleep for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11273147

Group type: EXPERIMENTAL
Intervention: Losartan therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study: 9266391

Group type: EXPERIMENTAL
Intervention: Oral uridine powder at 150 mg/kg per day (divided dose, three times daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dietary restriction (control group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Uridine treatment started prior to age 14 months
Number of subjects: 35
Study: 7884218

Group type: EXPERIMENTAL
Intervention: 14 days of intravenous ceftriaxone alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftriaxone followed by 100 days of amoxycillin plus probenecid
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftriaxone followed by 100 days of cephadroxil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Successful treatments
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Final titres less than 30% of the initial titre
Number of subjects: 100
Study: 2455152

Group type: EXPERIMENTAL
Intervention: Enalaprilat (5 mg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine (10 mg p.o.)
Number of subjects: 0
Study: 31410475

Group type: EXPERIMENTAL
Intervention: Visual games (yes)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Auditory games (yes)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Combined visual and auditory training
Number of subjects: 151

Group type: COMPARATOR
Intervention: Auditory games (no)
Number of subjects: 151
Study: 29475056

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy protocol for the prevention of suicide
Number of subjects: 185
Study: 27595681

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 3850

Group type: COMPARATOR
Intervention: Aspirin (ASA) 100 mg once daily
Number of subjects: 3850
Study: 24682206

Group type: EXPERIMENTAL
Intervention: 40 h sleep deprivation
Number of subjects: 24

Group type: COMPARATOR
Intervention: 40 h multiple naps
Number of subjects: 24
Study: 22075170

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 16114

Group type: COMPARATOR
Intervention: Control hepatitis A vaccine
Number of subjects: 16114
Study: 20961244

Group type: EXPERIMENTAL
Intervention: Weekly self-testing at home
Number of subjects: 2922

Group type: COMPARATOR
Intervention: Monthly high-quality testing in a clinic
Number of subjects: 2922
Study: 18178039

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg/70 kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Triazolam 0.12 mg/70 kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Triazolam (various doses: 0.00, 0.06, 0.12, and 0.25 mg/70 kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 16189252

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor letrozole (Lz; 2.5 mg/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 31
Study: 12556156

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 malaria vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10984729

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Even Briefer Assessment Scale for Depression (EBAS DEP)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Single question test for depression
Number of subjects: 173

Group type: COMPARATOR
Intervention: GDS and EBAS DEP
Number of subjects: 173
Study: 8666320

Group type: EXPERIMENTAL
Intervention: prednisolone followed by IFN‐alpha (n = 34)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: placebo followed by IFN‐alpha (n = 30)
Number of subjects: 95

Group type: COMPARATOR
Intervention: no treatment (control group, n = 31)
Number of subjects: 95
Study: 1546838

Group type: EXPERIMENTAL
Intervention: Closed-circuit method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Challenge room method
Number of subjects: 20
Study: 3927929

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30066020

Group type: EXPERIMENTAL
Intervention: 3D model No. 1 used in training group A for learning biliary tract anatomy and choledochoscopy techniques
Number of subjects: 20

Group type: COMPARATOR
Intervention: Virtual 3D image of the same model used in control group B
Number of subjects: 20
Study: 25800698

Group type: EXPERIMENTAL
Intervention: eSMART-MH
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 60
Study: 24467917

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program for Parents and Youth 10‐14 (SFP 10‐14), consisting of seven sessions and four booster-sessions.
Number of subjects: 288

Group type: COMPARATOR
Intervention: Minimal 2-hour intervention on parenting delivered in a school setting (Control).
Number of subjects: 288
Study: 23038102

Group type: EXPERIMENTAL
Intervention: High output vagus nerve stimulation (20 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low output vagus nerve stimulation (active control, 20 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High output vagus nerve stimulation (19 weeks after initial 20 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Baseline interleukin-6 levels
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Interleukin-1β changes
Number of subjects: 41
Study: 20437076

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (n = 15)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham vaccine (n = 9)
Number of subjects: 24
Study: 17549475

Group type: EXPERIMENTAL
Intervention: PLD 60 mg/m² (1st cycle), 30 mg/m² (2nd cycle), 45 mg/m² (3rd cycle)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m² (1st cycle), 60 mg/m² (2nd cycle), 45 mg/m² (3rd cycle)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PLD (all doses across cycles)
Number of subjects: 15
Study: 15920405

Group type: EXPERIMENTAL
Intervention: Transfused trauma patients with microchimerism
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-transfused trauma patients and healthy controls
Number of subjects: 63
Study: 14507797

Group type: EXPERIMENTAL
Intervention: Multimedia touchscreen computer (MTS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Patient information leaflet (PIL)
Number of subjects: 105
Study: 10863615

Group type: EXPERIMENTAL
Intervention: Amodiaquine (35 mg/kg over 3 days: 1st day: 15 mg/kg; 2nd day: 10 mg/kg; 3rd day: 10 mg/kg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (self-medication)
Number of subjects: 105
Study: 8779379

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg (Groups B, C, D, E, F)
Number of subjects: 138

Group type: COMPARATOR
Intervention: No ranitidine (Group A)
Number of subjects: 138
Study: 1502972

Group type: EXPERIMENTAL
Intervention: Desipramine (6-week double-blind outpatient trial)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no history of substance abuse)
Number of subjects: 75
Study: 6627221

Group type: EXPERIMENTAL
Intervention: Segmental mastectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total mastectomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Segmental mastectomy with resection margin involvement
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Segmental mastectomy without resection margin involvement
Number of subjects: 200
Study: 30600690

Group type: EXPERIMENTAL
Intervention: Text message reminders + School-located influenza vaccination (SLIV)
Number of subjects: 15768

Group type: COMPARATOR
Intervention: School-located influenza vaccination (SLIV) alone
Number of subjects: 15768
Study: 30085953

Group type: EXPERIMENTAL
Intervention: Youth-Friendly Health Services (YFHS)
Number of subjects: 1000
Study: 26920136

Group type: EXPERIMENTAL
Intervention: Cow's milk-based beverage (CMBB) containing DHA, PDX, GOS, β-glucan, and other nutrients, consumed 3 servings/day for 28 weeks
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control cow's milk-based beverage
Number of subjects: 256
Study: 24504197

Group type: EXPERIMENTAL
Intervention: Dual-task condition (climbing while responding to words)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task condition (climbing without making word associations)
Number of subjects: 0
Study: 22326385

Group type: EXPERIMENTAL
Intervention: Anodal tDCS above the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 15
Study: 20171002

Group type: EXPERIMENTAL
Intervention: Rapid Sequence Airway (RSA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Rapid Sequence Intubation (RSI)
Number of subjects: 19
Study: 18520794

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound
Number of subjects: 66

Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 66
Study: 15945105

Group type: EXPERIMENTAL
Intervention: Standard ischemic preconditioning protocol (n = 10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual-care control group (n = 7)
Number of subjects: 17
Study: 12116725

Group type: EXPERIMENTAL
Intervention: 0.28% triclosan/5% pyrophosphate dentifrice
Number of subjects: 186

Group type: COMPARATOR
Intervention: NaF/silica negative control dentifrice
Number of subjects: 186
Study: 10023496

Group type: EXPERIMENTAL
Intervention: Classroom intervention
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Home study intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 178
Study: 7605984

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 2699465

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/die)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amitriptyline (75 mg/die)
Number of subjects: 28
Study: 31587812

Group type: EXPERIMENTAL
Intervention: Sotagliflozin (exact dosage and duration not specified)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Monitoring ketones (part of the intervention process)
Number of subjects: 41
Study: 27941020

Group type: EXPERIMENTAL
Intervention: SonR contractility sensor-guided optimization
Number of subjects: 998

Group type: COMPARATOR
Intervention: Echo-guided optimization
Number of subjects: 998
Study: 25070348

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 22991267

Group type: EXPERIMENTAL
Intervention: Potassium citrate 60 mmol/d
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Potassium citrate 90 mmol/d
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21788629

Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 531
Study: 18832600

Group type: EXPERIMENTAL
Intervention: Lumbar diskectomy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 1000
Study: 16950468

Group type: EXPERIMENTAL
Intervention: Biplane echocardiography
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Biplane-guided 3D echocardiography
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional 2D dobutamine stress echocardiography
Number of subjects: 50
Study: 14515062

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 10972601

Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antegrade cardioplegia
Number of subjects: 20
Study: 7494563

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m²) + Paclitaxel (135 mg/m² over 24 hours)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m²) + Cyclophosphamide (750 mg/m²)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Cisplatin + Paclitaxel
Number of subjects: 410

Group type: COMPARATOR
Intervention: Cisplatin + Cyclophosphamide
Number of subjects: 410
Study: 1527459

Group type: EXPERIMENTAL
Intervention: Cephalexin-metronidazole protocol for 10 days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Ampicillin, gentamicin, cephalexin and metronidazole (various combinations for 5 or 10 days)
Number of subjects: 122
Study: 3893039

Group type: EXPERIMENTAL
Intervention: 1.5 g acetylsalicylic acid (ASA) for two days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for two days
Number of subjects: 25
Study: 31805012

Group type: EXPERIMENTAL
Intervention: 600 mg NAC BID for 12 weeks then TID for 12 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1200 mg NAC BID for 12 weeks then TID for 12 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1800 mg NAC BID for 12 weeks then TID for 12 weeks
Number of subjects: 30
Study: 30376082

Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Number of IPV doses
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Socioeconomic levels
Number of subjects: 966
Study: 27261982

Group type: EXPERIMENTAL
Intervention: Moxibustion plus rehabilitation training (MRT group, n=44)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Rehabilitation training (RT group, n=40)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Moxibustion plus rehabilitation training (MRT group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Rehabilitation training (RT group)
Number of subjects: 84
Study: 24856623

Group type: EXPERIMENTAL
Intervention: Judicial monitoring
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stage of change
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stake in conformity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Legal factors
Number of subjects: 60
Study: 22633184

Group type: EXPERIMENTAL
Intervention: 2-titration group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single-titration group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 20977036

Group type: EXPERIMENTAL
Intervention: Gratitude condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hassles condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any event condition
Number of subjects: 0
Study: 18164168

Group type: EXPERIMENTAL
Intervention: Debiasing technique (participants listing advantages and disadvantages of each treatment)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no debiasing technique)
Number of subjects: 102
Study: 16289799

Group type: EXPERIMENTAL
Intervention: Active migraine subjects with anxiety alone
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Active migraine subjects with depression alone
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Active migraine subjects with both anxiety and depression
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Active migraine subjects with neither anxiety nor depression
Number of subjects: 1957

Group type: COMPARATOR
Intervention: Non-migraine subjects
Number of subjects: 1957
Study: 12118746

Group type: EXPERIMENTAL
Intervention: Heparin bonded extracorporeal circuits (group H)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain extracorporeal circuits (group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (group H and group C)
Number of subjects: 40
Study: 10094133

Group type: EXPERIMENTAL
Intervention: Serotonin 2A receptor variant (102T/C) in schizophrenic patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Clozapine treatment in schizophrenic patients
Number of subjects: 97

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 97
Study: 7747231

Group type: EXPERIMENTAL
Intervention: McKenzie method of treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Patient education in mini back school
Number of subjects: 89
Study: 2103969

Group type: EXPERIMENTAL
Intervention: Heparin-glucuronilglucosaminoglycane treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7408684

Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol (Prent)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31238304

Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional training (sit-to-stand exercise without HAL)
Number of subjects: 60
Study: 28697113

Group type: EXPERIMENTAL
Intervention: Paracervical block with 18 mL 1% lidocaine and 2 mL sodium bicarbonate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 41
Study: 24905767

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity physical activity
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lateral forefoot pressure
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lateral midfoot pressure
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Second toe pressure
Number of subjects: 73
Study: 23463624

Group type: EXPERIMENTAL
Intervention: Capecitabine and oral cyclophosphamide (CCy)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Capecitabine alone (C)
Number of subjects: 82
Study: 20813884

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg plus fluticasone propionate 500 μg, twice a day
Number of subjects: 5112
Study: 19481079

Group type: EXPERIMENTAL
Intervention: Combination of EVL, propranolol (dose titrated to reduce heart rate to 55 bpm), and ISMN (40 mg/day)
Number of subjects: 177

Group type: COMPARATOR
Intervention: EVL alone
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Combination of EVL, propranolol, and ISMN
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients in combination group
Number of subjects: 177

Group type: COMPARATOR
Intervention: Cirrhotic patients in EVL alone group
Number of subjects: 177
Study: 15783243

Group type: EXPERIMENTAL
Intervention: ximelagatran
Number of subjects: 6948

Group type: COMPARATOR
Intervention: comparator
Number of subjects: 6948
Study: 11916195

Group type: EXPERIMENTAL
Intervention: Ropivacaine gel (200 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Active ulcerative colitis
Number of subjects: 19
Study: 10414879

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (9MU/d) + zidovudine (2x250 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bleomycin (15 mg every 2 weeks) + zidovudine (2x250 mg/d)
Number of subjects: 26
Study: 8643806

Group type: EXPERIMENTAL
Intervention: counseling plus adventure experiences
Number of subjects: 84

Group type: COMPARATOR
Intervention: counseling only
Number of subjects: 84

Group type: COMPARATOR
Intervention: adventure only
Number of subjects: 84

Group type: COMPARATOR
Intervention: control
Number of subjects: 84
Study: 2205572

Group type: EXPERIMENTAL
Intervention: Early arthroscopy (within 48 h)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Delayed arthroscopy (3 to 21 days after the injury)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 6778187

Group type: EXPERIMENTAL
Intervention: Tocainide (750 mg i.v. during a 15-minute period followed by 800 mg orally and later 400 mg t.i.d.)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 29941389

Group type: EXPERIMENTAL
Intervention: Antimicrobial lubricant (n=385)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard lubricant (control group, n=347)
Number of subjects: 1000
Study: 28931991

Group type: EXPERIMENTAL
Intervention: Hamstring stretching
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nerve mobilization
Number of subjects: 22
Study: 25645168

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behavior therapy (iCBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Delayed-treatment waitlist control group
Number of subjects: 54
Study: 24025143

Group type: EXPERIMENTAL
Intervention: Combination therapy with ornithine aspartate plus naloxone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Traditional medical treatment
Number of subjects: 84
Study: 21429443

Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg/1 ml
Number of subjects: 250

Group type: COMPARATOR
Intervention: diclofenac 75 mg/3 ml
Number of subjects: 250
Study: 18771676

Group type: EXPERIMENTAL
Intervention: Random number generation (RNG) of digits from 1 to 6
Number of subjects: 19

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 19
Study: 17161227

Group type: EXPERIMENTAL
Intervention: Soluble fiber (Konjac-mannan, 3g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 15213041

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (1000 IU RRR-alpha-tocopherol/d)
Number of subjects: 70
Study: 11430960

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 149

Group type: COMPARATOR
Intervention: Saline controls
Number of subjects: 149

Group type: COMPARATOR
Intervention: Other tocolytic agents
Number of subjects: 149
Study: 10211065

Group type: EXPERIMENTAL
Intervention: Anatomical filter-based exposure equalization technique
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 533